Could A $775 Million Roche-Blueprint Deal Unseat Eli Lilly In Cancer?

Could A $775 Million Roche-Blueprint Deal Unseat Eli Lilly In Cancer?

Blueprint Medicines stock popped Tuesday on a $775 million deal with pharma giant Roche to sell a cancer treatment, pralsetinib. The drug targets abnormalities in the RET gene.